Irina Rebin

Irina is member of the Practice Area Patents Technology & Life Sciences and the Life Sciences & Healthcare Industry Group. Her practice includes advising pharmaceutical, medical device, and biotechnology companies and investors on all regulatory matters throughout the entire life cycle of medicinal products, medical devices, and IVDs: from preclinical research and clinical trials, manufacturing, and market access to distribution (including post-market surveillance).

She also provides legal advice on genetic engineering, food (including food supplements), and cosmetics. Irina complements this practice focus by drafting and negotiating corresponding industry-specific agreements (including research and development agreements, license agreements, clinical trial agreements, contract/manufacturing and distribution agreements (including quality agreements)) and by advising on (cross-border) transactions in the healthcare sector.

CV

Since 2025 Salary Partner, Taylor Wessing

2020 - 2024 Associate/ Senior Associate

2020 Lawyer at a public corporation in the healthcare sector

职业发展

Since 2025 Salary Partner, Taylor Wessing

2020 - 2024 Associate/ Senior Associate

2020 Lawyer at a public corporation in the healthcare sector

教育

2019 Second state examination, Munich

2014 – 2017 Doctoral studies at Ludwig Maximilians University Munich

2014 - 2015 Doctoral studies at Georg August University Göttingen

Publications

§§ 40-42e AMG in: Rehmann, AMG, 6. Aufl. [in Bearb./vor. Anfang 2026] § 15 Entwicklung des Arzneimittelprüfrechts

§ 16 Grundlagen klinischer Arzneimittelprüfungen

§ 17 Zentrale Voraussetzungen klinischer Prüfungen im Überblick in: Spickhoff/Handorn: Handbuch Medizinisches Forschungsrecht, C. H. Beck, München, 2023

§ 2 ProdHaftG im Beck-Online-Großkommentar (seit 2015)

语言

奖励

JUVE Awards 2023

Featured

最新新闻和观点

View Irina's insights

点击此处了解更多

医疗器械

Update: AI-Enabled Medical Devices and IVDs Confirmed as “High-Risk”

2026年7月2日

作者 Irina Rebin

International Life Sciences Newsletter - Life Sciences Legal Lens Vol. 2

Medical Cannabis Platforms Breach Advertising Ban

Case law – German Federal Court of Justice (Bundesgerichtshof) – Online platforms brokering medical cannabis treatments breach the prohibition of public advertising under the German Healthcare Advertising Act

2026年7月2日

Briefing

作者 Irina Rebin

7 / 9 观点

点击此处了解更多

International Life Sciences Newsletter - Life Sciences Legal Lens Vol. 2

CJEU on distributor's verification obligations under MDR

Medical device (and IVD) distributors. CJEU confirms that distributors need not repeat the manufacturer’s classification or conformity assessment, but must perform a “consistency check” for obvious inconsistencies.

2026年7月1日

Briefing

作者 Irina Rebin

1 / 9 观点

点击此处了解更多

Irina Rebin

JUVE Awards 2023

专长

执业领域和服务团队

行业

CV

职业发展

教育

Publications

语言

奖励

JUVE Awards 2023

最新新闻和观点

Update: AI-Enabled Medical Devices and IVDs Confirmed as “High-Risk”

Irina Rebin

JUVE Awards 2023

专长

执业领域和服务团队

行业

CV

职业发展

教育

Publications

语言

奖励

JUVE Awards 2023

最新新闻和观点

Update: AI-Enabled Medical Devices and IVDs Confirmed as “High-Risk”

Related news & insights

The UPC’s first referral to the European Court of Justice: Cross-border preliminary injunctions against intermediaries and non-UPC defendants

Taylor Wessing advises co-lead investor East X Ventures on Proxima Fusion's € 411 million Series A-2 financing round

Hungarian supreme court on legal standing to challenge generic marketing authorisations

Case law – VfGH on the eImpfpass and central vaccination register

The new Product Liability Directive: three life sciences priorities before the 2026 deadline

Poland’s new AI systems act: a regulator and practical tools

France renews its simplified anti-gift conventions – what life sciences companies operating in France need to know

ARIHQ v. Santé Québec: Québec Superior Court set aside an arbitral award due to hallucinating AI

Life Sciences Legal Lens Vol. 2

EHDS implementation: preparing for health data access and reuse and what they should prepare before 2029

相关人员

与我会面：

Orphan and Breakthrough Devices: A New Route Through the MDR / IVDR Reform

Pharma Perspectives. Connecting Patents, Regulation and Strategy